BTG
"BTG" is a word mark owned by Protherics Medicines Development Limited, filed at the USPTO on October 27, 2009. It is registered and covers classes 1, 5, 10 and 42.
- Status
- Registered
- Since June 24, 2021
- Filed
- October 27, 2009
- Registered
- October 12, 2010
- Priority date
- August 10, 2009
- Claimed from United Kingdom
- Application no.
- 77858393
- Registration no.
- 3859363
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 4 classes
Who owns BTG
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Protherics Medicines Development Limited
London, United Kingdom
Representative
Jonathan A. Hyman
Knobbe, Martens, Olson & Bear, LLP
What the mark covers
The products and services BTG is filed for, grouped by Nice class.
[ Chemicals used in science; chemicals for clinical research use; diagnostic reagents and substances for clinical and medical laboratory use; diagnostic reagents and substances for clinical and medical laboratory in vitro research use; polyclonal antibodies and fragments thereof for clinical research use; diagnostic reagents and substances for in vivo clinical and laboratory research use; chemical reagents for scientific research use; chemicals used in science and medicine, namely, adjuvant compositions for use in the manufacture of vaccines and antibodies and antibody fragments for use in diagnostics and assays; cell lines for use in production of whole cell derived vaccines; cell lines for use in research related to virus mediated disease ]
Pharmaceutical and medicinal preparations and substances, namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations and substances for the treatment of thrombosis, [ inflammation, autoimmune disease and sleep disorders; dietetic foods adapted for medical use; ] vaccines; sera; polyclonal antibodies and fragments thereof for in vitro disease testing and for use in treating snake envenomation, overdose of toxic substances or sepsis; pharmaceutical preparations in the form of foams or for use in producing foams for use in sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins or arteriovenous malformations; chemical reagents for medical or veterinary purposes; chemical reagents for therapeutic and diagnostic purposes, namely, for the treatment of and the diagnosis of the presence of toxic substances; pharmaceutical preparations for the treatment of cancer; [ pharmaceutical preparations for the reduction or elimination of circulating cytokines; pharmaceutical preparations for the treatment of neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of pain, including headache and migraine; ] pharmaceutical preparations for promoting the healing of dermal wounds and chronic wounds including ulcers and pressure sores; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical preparations for the treatment of envenomation with snake venom; pharmaceutical preparations for treatment of excess levels of cancer agents; pharmaceutical preparations for the treatment of toxic levels of other pharmaceutical agents; pharmaceutical preparations for the treatment of cytotoxic cancer treatment drug overdose, particularly overdose with methotrexate; [ pharmaceutical preparations for the treatment of sleep apnea; pharmaceutical preparations for the treatment of head lice; ] diagnostic reagents for medical use and for the determination of levels of toxic substances in blood and tissue samples in vitro
Surgical apparatus for the treatment of varicose veins; medical syringes; cannula needles, medical tubing for administering drugs; surgical and medical apparatus for producing and administering pharmaceutical foams; surgical or medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices or hydroceles; devices for intravenous administration of pharmaceutical foam; diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose
[ Product research and development, namely, development of pharmaceuticals and medical devices through preclinical and clinical research in the fields of envenomation, drug overdose, chemical poisoning, venous disease, autoimmune disease, pain and inflammation and cancer therapy ]
What has happened so far
Steps recorded by the USPTO, newest first.
- Teas change of correspondence received
- Attorney/dom.rep.revoked and/or appointed
- Teas revoke/app/change addr of atty/dom rep received
- Applicant/correspondence changes (non-responsive) entered
- Teas change of owner address received
- Teas change of correspondence received
- Attorney/dom.rep.revoked and/or appointed
- Teas revoke/app/change addr of atty/dom rep received
- Applicant/correspondence changes (non-responsive) entered
- Teas change of correspondence received
10 earlier steps on the official record.
Oppositions and cancellations
Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.
About BTG
Who owns the trademark "BTG"?
The USPTO trademark "BTG" (application 77858393) is owned by Protherics Medicines Development Limited.
What is the status of "BTG"?
Its status at the USPTO is: registered.
When was "BTG" registered?
It was registered on October 12, 2010.
Get this data via the API
Everything on this page comes from the Signa API. Pull BTG and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d22c8-d05d-76c0-8fd9-0ea1b524bec1
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d22c8-d05d-76c0-8fd9-0ea1b524bec1",
"object": "trademark",
"mark_text": "BTG",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "77858393",
"filing_date": "2009-10-27",
"nice_classes": [
1,
5,
10,
42
],
"owners": [
{
"name": "PROTHERICS MEDICINES DEVELOPMENT LIMITED",
"entity_id": "ent_019eb7b8-00a8-76a9-8244-c233eba0d02b"
}
]
}